Withholding of Evidence Related to Offer for Sale, Filing False Declaration and Coercion by Patentee Support Finding of Inequitable Conduct

Mar 9, 2020

Reading Time : 3 min

GS CleanTech Corporation and Greenshift Corporation (collectively, “CleanTech”) sued a collection of companies in the ethanol industry for infringing patents directed to the recovery of oil from “thin stillage”—a byproduct of ethanol production. The lawsuits were combined into a multidistrict litigation, and the defendants moved for summary judgment on multiple grounds. Relevant here, the district court found certain claims invalid because of the on-sale bar under pre-AIA section 35 U.S.C. § 102(b).

The district court subsequently conducted an inequitable conduct bench trial and found that CleanTech and its prosecution counsel engaged in inequitable conduct before the USPTO with respect to four of the asserted patents. In particular, CleanTech made a mistake by offering its invention for sale more than a year before filing any patent applications, and then took affirmative steps to hide the offer after they learned it would prevent them from profiting off the patents-in-suit. The district court found CleanTech’s lawyers culpable as well because they purposefully avoided disclosing or failed to seek out relevant information, effectively placing advocacy over candor. In light of the inequitable conduct finding, the patents were deemed unenforceable. CleanTech appealed the lower court’s on-sale bar determination and its related finding of inequitable conduct.

The Federal Circuit affirmed the district court’s finding that the claimed invention was subject to the on-sale bar, which prohibits patents from issuing if, more than one year before filing, the invention was: (1) on sale or offered for sale; and (2) “ready for patenting.” The Federal Circuit agreed with the district court that a 2003 proposal sent by one of the inventors to Agri-Energy LLC constituted an offer for sale under the U.C.C. because it contained all of the elements of a contract for the sale of a system to perform the patented method. The court further held that successful testing of the oil recovery system during the same time period, as well as drawings and communications from an inventor, were sufficient to conclude that a person skilled in the art could have practiced the invention, i.e., that the claimed inventions were ready for patenting.

Similarly, the Federal Circuit found no error in the district court’s finding that CleanTech and its lawyers committed inequitable conduct before the USPTO, thus rendering the patents unenforceable. A patentee commits inequitable conduct if it: (1) knew about the prior art reference or prior commercial sale; (2) knew it was material; and (3) deliberately decided to withhold that information. See Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276, 1290 (Fed. Cir. 2011) (en banc). The Federal Circuit considered an array of evidence when rendering its decision on inequitable conduct.

Specifically, the court held that the inventors’ pre-filing research on the on-sale bar supported a finding that CleanTech knew its 2003 proposal threatened its chances of obtaining a patent. And, the evidence supported a finding that CleanTech and its lawyers withheld information from the USPTO. There was also evidence that both CleanTech and its lawyers attempted to coerce Agri-Energy into supporting its validity case. Namely, CleanTech offered Agri-Energy a royalty-free license if it admitted that the pending patents were valid. Likewise, CleanTech’s lawyers sent Agri-Energy an email offering to release the company from any liability in exchange for cooperating with CleanTech and requested a statement “confirming and clarifying” certain facts about the 2003 proposal. According to testimony from its manager, Agri-Energy declined “the offer from [CleanTech] because the statements were not true.” Finally, CleanTech’s lawyers filed a declaration executed by one of the inventors misrepresenting details about the 2003 proposal and then failed to correct that misrepresentation even though it “kn[e]w for certain” it was false.

Practice Tip: Counsel handling prosecution of a patent should, to the extent possible, take steps to confirm the information it receives from clients is both accurate and complete before disclosing it to the USPTO. Failure to do so may result in a finding of inequitable conduct by both the client and the prosecuting attorney.

GS Cleantech Corp. v. Adkins Energy LLC, No. 2016-2231 (Fed. Cir. Mar. 2, 2020)

Share This Insight

Previous Entries

IP Newsflash

November 14, 2025

The Ninth Circuit recently reversed a district court’s decision to strike a plaintiff’s trade secret claims under the Defend Trade Secrets Act (DTSA) at the discovery stage. In doing so, the Ninth Circuit made clear that under the DTSA, whether a party defined their trade secret with sufficient particularity is a question of fact that generally does not lend itself to resolution in the absence of at least some discovery. This ruling contrasts with the California Uniform Trade Secrets Act (CUTSA), which requires a party to define their trade secrets with reasonable particularity before commencing discovery.

...

Read More

IP Newsflash

November 11, 2025

The Federal Circuit recently vacated a summary judgment ruling of invalidity, holding that the district court erred in applying preclusive effect to the Patent Trial and Appeal Board’s unpatentability findings regarding other claims in the same patent. In doing so, the Federal Circuit reiterated that issue preclusion does not apply where the prior factual determinations were made under a lower standard of proof.

...

Read More

IP Newsflash

November 3, 2025

The Federal Circuit recently clarified the requirement for work disclosed in a reference to qualify as “by another” under pre-AIA Sections 102(a) and (e), holding that there must be complete inventive identity between the information disclosed in the asserted reference and the inventors named on the relevant patent. 

...

Read More

IP Newsflash

October 31, 2025

The District Court for the Northern District of California recently granted a defendant’s motion to bifurcate, ordering that issues related to PGR estoppel should be decided in a bench trial, while the remaining issues in the case should proceed to a jury trial.

...

Read More

IP Newsflash

October 31, 2025

The Northern District of Iowa recently held that a defendant’s motion for partial summary judgment of invalidity was barred after the PTAB issued final written decisions, regardless of when the motion was filed. The defendant filed its motion before the final written decisions were issued, but the court rejected the defendant’s argument that the timing of the motion insulated it from estoppel.

...

Read More

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.